J. Moreaux

J. Moreaux, R. Bras-Gonçalves, J. Lemesre, 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.

J. Moreaux, J. V. Van Ginderachter, A. Kassambara, 2019, Cancer letters.

Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients

B. Klein, J. Moreaux, T. Commes, 2014, BioMed research international.

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

G. Requirand, M. Jourdan, J. Moreaux, 2022, Frontiers in Immunology.

Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

J. Moreaux, Sara Ovejero, 2021, Exploration of targeted anti-tumor therapy.

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2017, Leukemia.

Role of Polycomb Complexes in Normal and Malignant Plasma Cells

J. Moreaux, Giacomo Cavalli, Sara Ovejero, 2020, International journal of molecular sciences.

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

T. Rème, J. Rossi, B. Klein, 2012, PloS one.

Kinome expression profiling to target new therapeutic avenues in multiple myeloma

M. Jourdan, J. Moreaux, D. Hose, 2019, Haematologica.

Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types

J. Moreaux, B. Győrffy, Giacomo Cavalli, 2021, Cancers.

Embryonic stem cell markers expression in cancers.

B. Klein, J. Moreaux, D. Hose, 2009, Biochemical and biophysical research communications.

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact

J. Moreaux, A. Kassambara, C. Bret, 2019, Journal of clinical medicine.

MMSET is overexpressed in cancers: link with tumor aggressiveness.

B. Klein, J. Moreaux, A. Kassambara, 2009, Biochemical and biophysical research communications.

APRIL is overexpressed in cancer: link with tumor progression

B. Klein, J. Moreaux, J. de Vos, 2009, BMC Cancer.

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

V. Pantesco, T. Rème, B. Klein, 2012, Haematologica.

Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study

J. Moreaux, S. Leprêtre, R. Letestu, 2021, Leukemia & lymphoma.

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

B. Klein, J. Moreaux, T. Commes, 2012, Oncotarget.

Physiological and druggable skipping of immunoglobulin variable exons in plasma cells

J. Moreaux, E. Pinaud, M. Cogné, 2018, Cellular & Molecular Immunology.

Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma

J. Moreaux, M. Cogné, M. Lutzmann, 2021, Cancers.

Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins

M. Jourdan, B. Klein, J. Moreaux, 2012, Leukemia.

Microarray‐based understanding of normal and malignant plasma cells

K. Tarte, T. Rème, M. Jourdan, 2006, Immunological reviews.

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

B. Klein, J. Moreaux, G. Cartron, 2019, Cancers.

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2014, Oncotarget.

Discovery of candidate DNA methylation cancer driver genes.

A. Gnirke, O. Elemento, J. Moreaux, 2021, Cancer discovery.

Targeting the β2‐adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism

J. Moreaux, G. Ateş, E. Sloan, 2022, The Journal of pathology.

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

V. Pantesco, T. Rème, J. Rossi, 2005, Blood.

BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone

K. Tarte, T. Rème, J. Rossi, 2003 .

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

J. D. Vos, G. Requirand, T. Rème, 2006, Oncogene.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

G. Requirand, J. Moreaux, D. Hose, 2018, Clinical Epigenetics.

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5

J. Moreaux, M. De Grandis, M. Aurrand-Lions, 2021, Blood advances.

EZH2 in normal hematopoiesis and hematological malignancies

B. Klein, J. Moreaux, Giacomo Cavalli, 2015, Oncotarget.

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma

G. Requirand, J. Moreaux, G. Papadopoulos, 2020, Theranostics.

LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms

J. Moreaux, F. Van Laethem, V. Lacheretz-Szablewski, 2022, International journal of molecular sciences.

DNA repair pathways in human multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2013, Cell cycle.

Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites

J. Moreaux, A. Constantinou, M. Méchali, 2018, bioRxiv.

Immunotherapy perspectives in the new era of B-cell editing.

J. Moreaux, M. Cogné, Y. Danger, 2021, Blood advances.

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value

B. Klein, J. Moreaux, P. Pasero, 2016, Biomarker Research.

Transient loss of Polycomb components induces an epigenetic cancer fate

J. Moreaux, B. Győrffy, Giacomo Cavalli, 2023, bioRxiv.

DNA methylation score is predictive of myeloma cell sensitivity to 5‐azacitidine

B. Klein, J. Moreaux, D. Hose, 2014, British journal of haematology.

DNA repair in diffuse large B‐cell lymphoma: a molecular portrait

B. Klein, J. Moreaux, A. Constantinou, 2015, British journal of haematology.

Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma

B. Klein, J. Moreaux, C. Bret, 2013, Cell cycle.

APRIL and TACI interact with syndecan‐1 on the surface of multiple myeloma cells to form an essential survival loop

M. Jourdan, J. Rossi, B. Klein, 2009, European journal of haematology.

TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

T. Rème, M. Jourdan, B. Klein, 2007, Haematologica.

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

G. Requirand, T. Rème, B. Klein, 2013, British Journal of Cancer.

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

T. Rème, B. Klein, J. Moreaux, 2013, PloS one.

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Bart Barlogie, Hartmut Goldschmidt, Dirk Hose, 2009, Blood.

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

J. Moreaux, K. Vanderkerken, H. de Raeve, 2019, Blood Cancer Journal.

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma

O. Elemento, G. Requirand, J. Moreaux, 2021, Journal of personalized medicine.

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy

J. Moreaux, A. Kassambara, G. Cartron, 2018, Oncotarget.

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

T. Rème, M. Jourdan, J. Rossi, 2010, BMC Cancer.

A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment

J. Moreaux, J. de Vos, J. Veyrune, 2020, Journal of clinical medicine.

Pivotal role of PIM2 kinase in plasmablast generation and plasma cell survival, opening new treatment options in myeloma.

K. Tarte, J. Moreaux, T. Fest, 2022, Blood.

Immunophenotyping by Flow Cytometry in Multiple Myeloma: Advantages for Diagnosis and Minimal Residual Disease Monitoring

G. Requirand, J. Moreaux, A. Caraux, 2012 .

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2016, British Journal of Cancer.

Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.

J. Moreaux, P. Vincendeau, P. Holzmuller, 2005, Veterinary immunology and immunopathology.

Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications

T. Rème, M. Jourdan, J. Rossi, 2007, Clinical Cancer Research.

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma

J. Moreaux, E. Julien, C. Grimaud, 2019, Clinical Epigenetics.

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Axel Benner, Thomas Hielscher, Bart Barlogie, 2008, Blood.

The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.

T. Rème, B. Klein, J. Moreaux, 2011, Srpski arhiv za celokupno lekarstvo.

MYEOV is a prognostic factor in multiple myeloma.

T. Rème, B. Klein, J. Moreaux, 2010, Experimental hematology.

Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma

J. Moreaux, C. Bret, C. Gourzonès, 2019, Front. Genet..

Characterization of human FCRL4-positive B cells

K. Tarte, M. Jourdan, B. Klein, 2017, PloS one.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

J. Moreaux, D. Hose, A. Kassambara, 2017, Cancer Immunology Research.

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.

B. Klein, J. Moreaux, R. Bataille, 2012, Blood cells, molecules & diseases.

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators

O. Elemento, M. Jourdan, J. Moreaux, 2021, Leukemia.

Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner

J. Moreaux, M. Lacroix-Triki, J. Choudhary, 2019, Nature Communications.

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.

G. Requirand, J. Moreaux, N. Robert, 2021, Blood advances.

Regulation of oncogene-induced senescence by the MRE11 and TREX1 nucleases

J. Moreaux, P. Pasero, Yea-Lih Lin, 2023, bioRxiv.

Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner

J. Moreaux, M. Lacroix-Triki, J. Choudhary, 2019, Nature Communications.

Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage

V. Pantesco, M. Jourdan, B. Klein, 2016, Cell cycle.

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

J. Moreaux, F. Offner, M. Spaargaren, 2019, British Journal of Cancer.

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

G. Requirand, T. Rème, B. Klein, 2012, Molecular Cancer Therapeutics.

MCT-12-0721 2685..2692

G. Requirand, T. Rème, B. Klein, 2012 .

Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features

B. Klein, J. Moreaux, C. Bony, 2020, Stem Cell Research & Therapy.

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].

J. Moreaux, Giacomo Cavalli, Laurie Herviou, 2018, Bulletin du Cancer.

Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

B. Klein, J. Moreaux, D. Hose, 2013, Haematologica.

CCR2 (chemokine (C-C motif) receptor 2)

J. Moreaux, 2012 .

BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone

K. Tarte, T. Rème, J. Rossi, 2003 .

A Phase I/II Study of TACI-Ig To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma or Active Previously-Treated Waldenström’s Macroglobulinemia.

G. Requirand, J. Rossi, B. Klein, 2005 .

A Phase I/II Study of Atacicept (TACI-Ig) To Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Multiple Myeloma (MM) or Active Previously Treated Waldenstrom’s Macroglobulinemia (WM).

J. Rossi, B. Klein, J. Moreaux, 2006 .

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients

J. Moreaux, F. Ghiringhelli, B. Manfroi, 2018, Blood Cancer Journal.

NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm

B. Klein, J. Moreaux, D. Hose, 2010, Genes, chromosomes & cancer.

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

J. Moreaux, F. Offner, M. Spaargaren, 2019, British Journal of Cancer.

[Diaphragmatic hernias in adults].

J. Moreaux, 1997, La Revue du praticien.

The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

B. Klein, J. Moreaux, D. Hose, 2015, Haematologica.

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value

B. Klein, J. Moreaux, P. Pasero, 2016, Biomarker Research.

Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features

B. Klein, J. Moreaux, C. Bony, 2020, Stem Cell Research & Therapy.

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

K. Tarte, T. Rème, J. Rossi, 2004, Blood.

3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness.

J. Moreaux, B. Bogen, A. Zeller, 2023, Matrix biology : journal of the International Society for Matrix Biology.

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

K. Tarte, T. Rème, J. Rossi, 2003 .

New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients

J. Moreaux, K. Mills, A. Boureux, 2012, British journal of haematology.

DNA repair pathways in human multiple myeloma

T. Rème, B. Klein, J. Moreaux, 2013, Cell cycle.

Gene expression-based risk score in diffuse large B-cell lymphoma

B. Klein, J. Moreaux, C. Bret, 2012, Oncotarget.

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact

J. Moreaux, A. Kassambara, C. Bret, 2019, Journal of clinical medicine.

Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.

J. Moreaux, D. Hose, C. Heirman, 2018, Cancer research.

Physiological and druggable skipping of immunoglobulin variable exons in plasma cells

J. Moreaux, E. Pinaud, M. Cogné, 2018, Cellular & Molecular Immunology.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

T. Rème, J. Rossi, B. Klein, 2011, Haematologica.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

G. Requirand, J. Moreaux, D. Hose, 2018, Clinical Epigenetics.

Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse 1 Large B-Cell Lymphoma 2

J. Moreaux, T. Cañeque, L. Mondoulet, 2022 .

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

T. Rème, M. Jourdan, B. Klein, 2011, Haematologica.

Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data

J. Moreaux, Eric Soler, M. Salma, 2023, Epigenetics & Chromatin.

BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone

K. Tarte, J. Rossi, B. Klein, 2003 .

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma

G. Requirand, J. Moreaux, G. Papadopoulos, 2022, Theranostics.

Comprehensive characterization of the epigenetic landscape in Multiple 1 Myeloma 2

G. Requirand, J. Moreaux, J. Martín-Subero, 2021 .

Immunophenotypic portrait of leukemia‐associated‐phenotype markers in B acute lymphoblastic leukemia

J. Moreaux, C. Bret, Emilia Boris, 2023, Cytometry. Part B, Clinical cytometry.

Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation.

J. Moreaux, J. Martín-Subero, P. Milpied, 2024, Blood.

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].

J. Moreaux, Giacomo Cavalli, Laurie Herviou, 2018, Bulletin du cancer.

New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients

J. Moreaux, K. Mills, A. Boureux, 2012, British journal of haematology.

Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

V. Pantesco, T. Rème, B. Klein, 2012, Haematologica.

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma

G. Requirand, J. Moreaux, Sara Ovejero, 2023, Frontiers in oncology.

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

G. Requirand, J. Rossi, B. Klein, 2012, Oncotarget.

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma

J. Moreaux, C. Berkers, K. Vanderkerken, 2023, Haematologica.

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

G. Requirand, T. Rème, B. Klein, 2011, Blood.